TG Therapeutics Inc (USD)
TGTX
Overview
Key Information
Legal Documents
Financials

Overview

SectorHealthcare
Industry-
Day Range48.56 | 51.54
52-Wk Range- | -
Last Close49.62
Mkt Cap (m)6,838.14
Dividend yield-
ISINUS88322Q1085
Volume1,810,862.00
Exchange VenueNAS

Company Profile

TG Therapeutics Inc is a biopharmaceutical company. It is engaged in the acquisition, development & commercialization of novel treatments for B-cell malignancies and autoimmune diseases.

Key Information
Price/Earning-
Price/Book40.00
Price/Sales35,328.31
P/CF-
Rev Growth (3 year avg)-
EPS Growth (3 year avg)-
Operating Margin % -
Net Margin %-
Return on Equity-
Debt/Equity-

Documents

Prospectus
en 16/12/2020
Annual Report
en 31/12/2019

Please refer to the below issuer website for further documents.

http://www.tgtherapeutics.com

Financials

Income Statement
USD201520162017201820192020
Revenue (m)0.150.150.150.150.15-
Operating Income (m)-63.18-78.97-118.71-174.40-169.06-
Net Income (m)-62.95-78.25-118.48-173.48-172.87-
Basic EPS-1.38-1.60-1.91-2.30-1.96-
Avg. Diluted Shares Outstanding (m)45.6549.0462.0775.4788.37-
Balance Sheet
USD201520162017201820192020
Current Assets (m)86.8750.8693.3279.03149.15-
Non Current Assets (m)26.603.924.064.5913.86-
Total Assets (m)113.4754.7897.3883.62163.01-
Current Liabilities (m)10.5316.8827.9638.8584.45-
Total Liabilities (m)------
Total Equity (m)101.5735.8766.9924.0438.62-
Cash Flows
USD201520162017201820192020
Operating Cash Flows (m)-44.69-61.59-93.76-128.93-132.81-
Capital Expenditure (m)-0.04-0.340.00-0.09-0.13-
Figures are quoted in USD unless stated otherwise
-
No change
$
49.62
Last Price